Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 13/20 | 0.67 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.60 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19778762 | 0.91 | PLK1 (0.58) | PLK1PLK3TRPM2CYP1A2CYP2C19 | |
| SCHEMBL19778994 | 0.87 | SMN1; SMN2 (0.53) | PLK1PLK3TRPM2CYP1A2CYP2C19 | |
| SCHEMBL9147396 | 0.85 | PLK1 (0.50) | PLK1PLK3CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL10489832 | 0.84 | CYP1A2 (0.71) | PLK1PLK3CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL8108517 | 0.84 | PLK1 (0.63) | PLK1PLK3TRPM2CYP1A2CYP2C19 | |
| SCHEMBL5808126 | 0.83 | CYP1A2 (0.52) | PLK1CYP1A2CYP2C19SMN1; SMN2CYP2C9 | |
| SCHEMBL10489932 | 0.82 | CYP1A2 (0.59) | PLK1PLK3CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL5720784 | 0.82 | SMN1; SMN2 (0.55) | PLK1CYP1A2CYP2C19SMN1; SMN2CYP2C9 | |
| SCHEMBL10489833 | 0.81 | METAP2 (0.55) | PLK1PLK3TRPM2CYP1A2CYP2C19 | |
| SCHEMBL10490025 | 0.81 | CYP1A2 (0.54) | PLK1PLK3TRPM2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105884706-B | Efficient synthesis method of cetilistat | 南京海纳医药科技股份有限公司 | 2020-07-03 | — | — | CN | claimed |
| WO-2018011676-A1 | NOVEL PROCESSES FOR THE PREPARATION OF 2-OXY-BENZOXAZINONE DERIVATIVES | SYMED LABS LIMITED (IN) | 2018-01-18 | — | — | WO | claimed |
| CN-105884706-B | Efficient synthesis method of cetilistat | 南京海纳医药科技股份有限公司 | 2020-07-03 | — | — | CN | disclosed |
| WO-2018011676-A1 | NOVEL PROCESSES FOR THE PREPARATION OF 2-OXY-BENZOXAZINONE DERIVATIVES | SYMED LABS LIMITED (IN) | 2018-01-18 | — | — | WO | disclosed |
| WO-2018011676-A1 | NOVEL PROCESSES FOR THE PREPARATION OF 2-OXY-BENZOXAZINONE DERIVATIVES | SYMED LABS LIMITED (IN) | 2018-01-18 | — | — | WO | disclosed |
| CN-105646287-A | Method for preparing important intermediate 2- (hexadecyloxycarbonyl) -amino-5-methylbenzoic acid of Cetilistat | 南京工业大学 | 2016-06-08 | — | — | CN | disclosed |
| US-20080171891-A1 | Process for preparing carbamic ester derivatives | HOLZER BETTINA | 2008-07-17 | — | — | US | disclosed |
| US-20080171891-A1 | Process for preparing carbamic ester derivatives | HOLZER BETTINA | 2008-07-17 | — | — | US | disclosed |
| US-7396952-B2 | Process for preparing carbamic ester derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2008-07-08 | — | — | US | disclosed |
| US-7396952-B2 | Process for preparing carbamic ester derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2008-07-08 | — | — | US | disclosed |
| US-20070232825-A1 | Process for preparing carbamic ester derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232825-A1 | Process for preparing carbamic ester derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| EP-1669346-A1 | Process for the preparation of carbamic acid derivatives | Lanxess Deutschland GmbH (DE) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171891-A1 | Process for preparing carbamic ester derivatives | CPS1, CA7, CA4 | PLK1 4473/4885PLK3 4226/4885TRPM2 4862/4885 |
| US-20070232825-A1 | Process for preparing carbamic ester derivatives | CPS1, CA7, CA4 | PLK1 4473/4885PLK3 4226/4885TRPM2 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.